Pre-made Onvatilimab benchmark antibody ( Whole mAb, anti-VSIR therapeutic antibody, Anti-B7-H5/B7H5/C10orf54/DD1alpha/Dies1/GI24/PD-1H/PP2135/SISP1/VISTA Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Onvatilimab biosimilar, Whole mAb, Anti-VSIR Antibody: Anti-B7-H5/B7H5/C10orf54/DD1alpha/Dies1/GI24/PD-1H/PP2135/SISP1/VISTA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-406-1mg	1mg	3090
GMP-Bios-ab-406-10mg	10mg	Inquiry
GMP-Bios-ab-406-100mg	100mg	Inquiry
GMP-Bios-ab-406-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Onvatilimab biosimilar, Whole mAb, Anti-VSIR Antibody: Anti-B7-H5/B7H5/C10orf54/DD1alpha/Dies1/GI24/PD-1H/PP2135/SISP1/VISTA therapeutic antibody
INN Name	Onvatilimab
Target	VSIR
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Janssen Research & Development
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na